{
    "organizations": [],
    "uuid": "76cfed4f30a391a5e460f78b48e561f3d39571d8",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-announces-tafamidis-phase-3/brief-pfizer-announces-tafamidis-phase-3-attr-act-study-met-its-primary-endpoint-idUSFWN1RB0Y8",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Announces Tafamidis Phase 3 ATTR-ACT Study Met Its Primary Endpoint",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29, 2018 / 4:51 PM / Updated 11 minutes ago BRIEF-Pfizer Announces Tafamidis Phase 3 ATTR-ACT Study Met Its Primary Endpoint Reuters Staff 1 Min Read \n  Pfizer Inc: \n* PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ATTR-ACT STUDY OF TAFAMIDIS IN PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY \n* PFIZER INC - STUDY MET ITS PRIMARY ENDPOINT \n* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED \n* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED IN POPULATION AND NO NEW SAFETY SIGNALS WERE IDENTIFIED Source text for Eikon: Further company coverage:",
    "published": "2018-03-29T19:49:00.000+03:00",
    "crawled": "2018-03-29T20:04:26.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "tafamidis",
        "phase",
        "study",
        "met",
        "primary",
        "endpoint",
        "reuters",
        "staff",
        "min",
        "read",
        "pfizer",
        "inc",
        "pfizer",
        "announces",
        "positive",
        "topline",
        "result",
        "phase",
        "study",
        "tafamidis",
        "patient",
        "transthyretin",
        "cardiomyopathy",
        "pfizer",
        "inc",
        "study",
        "met",
        "primary",
        "endpoint",
        "pfizer",
        "inc",
        "preliminary",
        "safety",
        "data",
        "showed",
        "tafamidis",
        "generally",
        "well",
        "tolerated",
        "pfizer",
        "inc",
        "preliminary",
        "safety",
        "data",
        "showed",
        "tafamidis",
        "generally",
        "well",
        "tolerated",
        "population",
        "new",
        "safety",
        "signal",
        "identified",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}